Powering The iPhone: Apple's Supply Chain Partners
Apple's recent record-breaking revenue highlights the success of its strategic supply chain diversification. This creates a compelling investment opportunity in the key component and manufacturing partners that are essential to Apple's production ecosystem.
Your Basket's Financial Footprint
Parsed market capitalisation breakdown for the basket named 'Powering The iPhone: Apple's Supply Chain Partners'. Includes total market cap and constituent market caps.
- Large-cap dominance generally implies lower volatility and closer market tracking, so performance tends to be steadier, less speculative.
- Best considered a core holding for diversified portfolios, offering broad exposure rather than a speculative growth position.
- Expect steady long-term value appreciation rather than explosive short-term gains; outcomes are not guaranteed.
TSM: $1.23T
ASML: $400.56B
LRCX: $182.63B
- Other
About This Group of Stocks
Our Expert Thinking
Apple's record-breaking $94.04 billion quarterly revenue, driven by strong iPhone 16 sales, creates a powerful ripple effect throughout its supply chain. As Apple ramps up production to meet sustained demand, the companies that manufacture semiconductors, camera modules, and provide assembly services are positioned to benefit directly from this success.
What You Need to Know
This group focuses on the essential but often overlooked partners in Apple's manufacturing ecosystem. These companies range from advanced semiconductor manufacturers to component suppliers, all playing critical roles in bringing iPhones to market. Their fortunes are closely tied to Apple's continued market leadership and production needs.
Why These Stocks
Each company in this group has been handpicked by professional analysts based on their integral role in Apple's supply chain diversification strategy. These aren't random tech stocks - they're the specific manufacturers and suppliers that Apple relies on to maintain its production capabilities and meet global demand.
Why You'll Want to Watch These Stocks
Riding Apple's Record Success
With Apple's $94.04 billion quarterly revenue beating expectations, these supply chain partners are positioned to benefit directly from increased production demands and sustained iPhone momentum.
Essential Links in the Chain
These aren't just any tech companies - they're the critical manufacturers and suppliers that Apple depends on for semiconductors, components, and assembly services to keep iPhones flowing to market.
Strategic Diversification Play
Apple's supply chain diversification strategy creates opportunities for multiple partners across different regions, reducing single-point risks while opening doors for growth across the ecosystem.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Tech Stocks (AI Valuation Reset) Present Potential Entry
Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.
Walmart Succession Plan Explained | Market Effects
Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.